Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,001 - 1,050 out of 12,084

Document Document Title
WO/2007/079186A2
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosc...  
WO/2007/078523A2
The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employe...  
WO/2007/074477A3
The invention provides two crystalline forms A and B of the skeletal muscle relaxant and anxiolytic agent, Metaxalone of formula (I), and a process for preparation thereof. The two crystalline forms A and B are bioavailable. The inventio...  
WO/2007/074477A2
The invention provides two crystalline forms A and B of the skeletal muscle relaxant and anxiolytic agent, Metaxalone of formula (I), and a process for preparation thereof. The two crystalline forms A and B are bioavailable. The inventio...  
WO/2007/075870A2
The application provides a process for the preparation of taxane derivatives and intermediates useful in such processes.  
WO/2007/075870A3
The application provides a process for the preparation of taxane derivatives and intermediates useful in such processes.  
WO/2007/073699A1
5,5'-linked 1,1'-biphenyl axial chiral ligands in the field of chemical engineering technique are disclosed. The present ligands have both central chirality of oxazoline and axial chirality of biphenyl. The present ligands are expected t...  
WO/2007/073518A2
Methods for therapy of cystic fibrosis and other conditions such as cancer are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters s...  
WO/2007/073518A3
Methods for therapy of cystic fibrosis and other conditions such as cancer are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters s...  
WO/2007/073296A1
The present invention relates to novel thiazole and oxazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a ...  
WO/2007/068815A3
The invention concerns compounds of formula (I) wherein: X represents a -C-, -SO2-, -C-N(R5)-C-N(R5)- group; Y represents an oxygen atom or a sulphur atom; R1 represents a hydrogen atom or a C1-C4 alkyl group; R2 represents a C1-C7 alkyl...  
WO/2007/069773A1
The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene rin...  
WO/2007/068815A2
The invention concerns compounds of formula (I) wherein: X represents a -C-, -SO2-, -C-N(R5)-C-N(R5)- group; Y represents an oxygen atom or a sulphur atom; R1 represents a hydrogen atom or a C1-C4 alkyl group; R2 represents a C1-C7 alkyl...  
WO/2007/065821A1
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula (I) and pharmace...  
WO/2007/066617A1
Disclosed is a method for producing an azoline compound represented by the general formula (3) below, which is characterized in that a carboxylic acid or a carboxylic acid derivative represented by the general formula (1) below is reacte...  
WO/2007/065828A1
The present invention relates to compounds of formula (I) wherein A, X, R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and phar...  
WO/2007/067501A1
A process for the enantio selective synthesis of an (S)- or (R)- l-[2- dimethylamino)-l-(methoxyphenyl)ethyl]cyclohexanol and analogues or salt thereof are described. The method involves the steps of (a) reacting an (S) or (R) 4- benzylo...  
WO/2007/063789A1
Disclosed are a compound having a strong COMT inhibitory effect and represented by the general formula (I) below, a pharmacologically acceptable salt thereof, a pharmaceutical composition containing either of them, and uses of them. (I) ...  
WO/2007/063839A1
Disclosed is a cyclohexane derivative represented by the formula (I), which can bind specifically to an NR1/NR2B receptor and therefore can be used as an analgesic agent (a therapeutic agent for pain): (I) wherein A1 represents a (substi...  
WO/2007/063702A3
The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition.  
WO/2007/064818A1
The present invention provides an isolated linezolid impurity, desfluoro linezolid, the preparation thereof and its use as a reference standard.  
WO/2007/064749A1
This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, T...  
WO/2007/064316A1
The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. ...  
WO/2007/063946A1
It is intended to provide a diagnostic which specifically binds to an amyloid aggregate or deposit and thus enables the visualization or quantification of a disease caused by the amyloid aggregation and/or deposition. Namely, a compound ...  
WO/2007/060121A1
The present invention relates to Indanyl- and Tetrahydronaphthyl-amino-azoline compounds of formula (I) wherein the variables R1 and R2 are as defined in description. The invention relates also to methods of combating or controlling inse...  
WO/2007/060526A1
The invention relates to substituted azacycloalkaπe compounds useful in treating conditions of the Central Nervous System (CNS); a pharmaceutical composition comprising same; a method of treating such conditions and of treating conditio...  
WO/2007/062316A2
A compound of Formula I is disclosed, in which R is a substituent containing a hydrogen bond-forming atom within three atoms from the ring carbon to which the substituent is bonded; X is CH2, 0, S or NR1, wherein Rl is a hydrocarbyl grou...  
WO/2007/062316A3
A compound of Formula I is disclosed, in which R is a substituent containing a hydrogen bond-forming atom within three atoms from the ring carbon to which the substituent is bonded; X is CH2, 0, S or NR1, wherein Rl is a hydrocarbyl grou...  
WO/2007/058338A2
The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group ea...  
WO/2007/058338A3
The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group ea...  
WO/2007/056366A2
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated R...  
WO/2007/056366A3
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated R...  
WO/2007/056496A1
The invention provides compounds (I) pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activate...  
WO/2007/056469A3
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2007/055929A1
Polyfunctional cyclic carbonates provide a useful additional monomer for energy-initiated cationic copolymerisation with such other monomers and oligomers as epoxides and oxetanes.  
WO/2007/056469A2
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2007/052843A1
Disclosed is a FXR inhibitor comprising a compound represented by the formula (I') or a salt or a prodrug of the compound or salt: wherein each symbol is as defined in the description. The FXR inhibitor has an excellent FXR-inhibiting ef...  
WO/2007/048595A1
The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals.  
WO/2007/047306A1
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal depositi...  
WO/2007/042816A1
There is provided the use of a compound of formula (I),wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a ...  
WO/2007/043400A1
Disclosed are: a novel compound having one or both of a xanthine oxidase inhibitory activity and an uric acid excretion promoting activity; a pharmaceutical composition comprising the compound as an active ingredient; use of the compound...  
WO/2007/044565A3
The present invention provides compounds and compositions for inhibiting Vif and methods for treating viral infection, e.g., HIV infection.  
WO/2007/043401A1
Disclosed are: a novel compound having a xanthine oxidase inhibitory activity and an uric acid excretion promoting activity; and a pharmaceutical composition comprising the compound as an active ingredient. The compound is a nitrogenated...  
WO/2007/037010A1
It is intended to provide a novel compound having an excellent agonism to PPARs α/γ and desirable properties as a drug. An agonist to peroxisome proliferator-activated receptors α/γ which is represented by the general formula (I) (wh...  
WO/2007/037187A1
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represent...  
WO/2007/034251A1
The present invention relates to the CCR3 receptor ligands of the general formula (I), within them favourably to antagonists and to the salts, solvates and isomers thereof, to the pharmaceutical compositions containing them, to the use o...  
WO/2007/034254A3
The present invention relates to the CCR3 receptor ligands of the general formula (I), within them favourably to antagonists and to the salts, solvates and isomers thereof, to the pharmaceutical compositions containing them, to the use o...  
WO/2007/034254A2
The present invention relates to the CCR3 receptor ligands of the general formula (I), within them favourably to antagonists and to the salts, solvates and isomers thereof, to the pharmaceutical compositions containing them, to the use o...  
WO/2007/034035A1
The invention relates to sulphonamide derivatives of formula (I), where Rc is selected from a group consisting of dialkylamino, NO2, CN, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl, oxazol-2-yl, oxazolylaminocar...  
WO/2007/032028A1
The present invention encompasses; the novel substituted heterocyclic compounds represented by formula (I) or their pharmaceutically acceptable salts, wherein the substituents in formula (I) have the meanings as defined in the specificat...  

Matches 1,001 - 1,050 out of 12,084